<div id="readability-page-1"><p>Signature Estate &amp; Investment Advisors LLC trimmed its stake in  Merck &amp; Co., Inc. (NYSE:MRK - Free Report) by 27.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,069 shares of the company's stock after selling 3,058 shares during the period. Signature Estate &amp; Investment Advisors LLC's holdings in Merck &amp; Co., Inc. were worth $639,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</span></p></div><ul><li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li></ul><p>Several other hedge funds have also bought and sold shares of the business. Barnes Dennig Private Wealth Management LLC bought a new position in shares of  Merck &amp; Co., Inc. during the first quarter valued at approximately $27,000.  Legend Financial Advisors Inc. bought a new position in shares of  Merck &amp; Co., Inc. during the second quarter valued at approximately $25,000.  CBIZ Investment Advisory Services LLC increased its stake in shares of  Merck &amp; Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company's stock valued at $34,000 after purchasing an additional 221 shares in the last quarter.  MorganRosel Wealth Management LLC bought a new position in shares of  Merck &amp; Co., Inc. during the first quarter valued at approximately $36,000.  Finally, Fiduciary Wealth Partners LLC bought a new position in shares of  Merck &amp; Co., Inc. during the first quarter valued at approximately $48,000. Institutional investors own  76.07% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>MRK has been the subject of a number of analyst reports. Wells Fargo &amp; Company decreased their target price on shares of Merck &amp; Co., Inc. from $97.00 to $90.00 and set an &#34;equal weight&#34; rating for the company in a research note on Wednesday, July 30th. Weiss Ratings  reaffirmed a &#34;hold (c-)&#34; rating on shares of Merck &amp; Co., Inc. in a report on Wednesday, October 8th. Berenberg Bank cut shares of Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and decreased their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup began coverage on shares of Merck &amp; Co., Inc. in a report on Monday, October 13th. They issued a &#34;neutral&#34; rating and a $95.00 target price for the company. Finally, Morgan Stanley decreased their target price on shares of Merck &amp; Co., Inc. from $99.00 to $98.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, July 10th. One research analyst  has rated the stock with a Strong Buy rating, five have assigned  a Buy rating, thirteen have given a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat, Merck &amp; Co., Inc. currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $104.33.</p><ul><li>5 Healthcare Plays Powering the Sector’s Big Comeback</li></ul><p><b>Read Our Latest Analysis on MRK</b></p><h2>Merck &amp; Co., Inc. Stock Performance</h2><p>Shares of MRK stock opened at $86.30 on Tuesday. The company has a 50 day moving average price of $84.03 and a 200-day moving average price of $81.35. Merck &amp; Co., Inc. has a 52 week low of $73.31 and a 52 week high of $109.17. The firm has a market capitalization of $215.56 billion, a PE ratio of 13.30, a P/E/G ratio of 0.93 and a beta of 0.37. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. </p><ul><li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li></ul><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.10. Merck &amp; Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion.  Merck &amp; Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities research analysts expect that  Merck &amp; Co., Inc. will post 9.01 earnings per share for the current year. </p><h2>About Merck &amp; Co., Inc.</h2> (Free Report)<p>Merck &amp; Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.</p><h2>Read More</h2><ul><li>Five stocks we like better than Merck &amp; Co., Inc.</li><li>How to Calculate Options Profits</li><li>Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet</li><li>Stock Market Upgrades: What Are They?</li><li>3 High-Yield Banks for Investors to Buy on the Dip</li><li>How to Use High Beta Stocks to Maximize Your Investing Profits</li><li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li></ul><p><strong>Want to see what other hedge funds are holding MRK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck &amp; Co., Inc. (NYSE:MRK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p><p>While Merck &amp; Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Signature Estate & Investment Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 27.5% in Q2, according to a recent SEC filing. After selling 3,058 shares, the firm now holds 8,069 shares valued at $639,000. Other hedge funds have also adjusted their positions in Merck. Analysts have set a consensus target price of $104.33 for the stock, which currently trades at $86.30, with a market cap of $215.56 billion and a PE ratio of 13.30.</p>

Signature Estate & Investment Advisors LLC Reduces Holdings in Merck & Co., Inc. $MRK